Combination of | |
---|---|
Darunavir | HIV protease inhibitor |
Cobicistat | Cytochrome P450 (CYP3A) inhibitor |
Clinical data | |
Trade names | Rezolsta, Prezcobix |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C67H90N10O12S3 |
Molar mass | 1323.70 g·mol−1 |
3D model (JSmol) | |
| |
|
Darunavir/cobicistat, sold under the brand names Prezcobix (US) and Rezolsta (EU), is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS.[3] It contains darunavir and cobicistat.[3][5][6] Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.[6][3]
Darunavir/cobicistat was approved for use in the European Union in November 2014, and for use in the United States in January 2015.[4][7][8][3][9]